(UroToday.com) In the on-demand poster session of the European Society for Medical Oncology (ESMO) Annual Congress, Dr. Guillermo De Velasco discussed the CABOPRE trial, a single-arm prospective multicentre phase II trial to assess the efficacy and safety of neoadjuvant cabozantinib in patients with clear cell metastatic renal cell carcinoma (mRCC) and potential candidates to cytoreductive nephrectomy (CN) (EudraCT Number: 2018-001201-93).